Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough

Previously Announced Statistically Significant Interim Analysis Established Proof of Concept (p-value less than 0.0001)

Efficacy and Safety Data Expected on the Full Set of Subjects in Third Quarter 2022

NEW HAVEN, Conn., March 15, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER). Today, Trevi announced that it concluded enrollment early for its Phase 2 Cough And NALbuphine (CANAL) trial for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) patients following the previously announced statistically significant efficacy results from the interim analysis (N=26). The primary efficacy endpoint demonstrated a 77.3% reduction in daytime cough frequency from baseline with the use of Haduvio compared to a 25.7% reduction with placebo, demonstrating a 52% placebo-adjusted reduction in the geometric mean percent change in the daytime cough frequency (p